Vascular Perfusion Solutions Teams Up with Harvard’s Wyss Institute
In a significant advancement for the medical field, Vascular Perfusion Solutions, Inc. (VPS) has announced a collaboration with the Wyss Institute at Harvard University, alongside both the University of Colorado and the University of Wyoming. This partnership is part of the Advanced Research Projects Agency for Health (ARPA-H) initiative focusing on Tissue Preservation under Stress (TiPS). The primary goal of this collaboration is to innovate biostasis compounds that can significantly enhance organ preservation methods.
Targeting Organ Preservation Challenges
The urgency for improved organ preservation strategies stems from the need to increase donor organ utilization and extend the preservation time for sensitive organs. VPS will spearhead the translational testing of these innovative compounds, striving to create a cutting-edge perfusion solution. This initiative is expected to enhance the safe preservation of organs, ultimately allowing for a broader range of viable donations.
Vision for Transplantation Equity
Rafael J. Veraza, PhD, MPH, who serves as the CEO and President of VPS, underscored the importance of their mission. He stated, "Extending the safe preservation window is essential to improving access and equity in transplantation." With this partnership, VPS aims to bridge the gap between advanced laboratory research and real-world applications, fostering the development of scalable solutions that can revolutionize organ transplantation.
The VP.S ENCORE Platform
VPS is at the forefront of advancing technology in the field of organ preservation with its VP.S ENCORE platform. This innovative system is designed to be simple and portable, allowing for the preservation of donor hearts and other vital organs for extended periods. By enabling longer preservation durations, VPS seeks to remove geographical barriers that currently hinder equitable access to organ transplants.
Ongoing Development and Investigation
The VP.S ENCORE platform remains in the investigational stage and is currently under development. It is essential to note that it has not yet received approval for commercial use from the FDA. However, the progress being made signifies a promising future for organ preservation methodologies.
Contacting VPS for More Information
Those interested in learning more about the advancements and initiatives of Vascular Perfusion Solutions are encouraged to reach out directly. Rafael Veraza can be contacted at 210-977-0191 for any media inquiries or further information.
Frequently Asked Questions
What is the focus of the collaboration between VPS and Harvard's Wyss Institute?
The focus is on developing biostasis compounds to enhance organ preservation techniques within the framework of a broader research initiative.
How does the VP.S ENCORE platform improve organ utilization?
By extending the preservation time of organs, the platform aims to increase the accessibility and availability of donor organs for transplantation.
Is the VP.S ENCORE platform currently approved for use?
No, the VP.S ENCORE platform is still in development and has not yet received FDA approval for commercial use.
What are the potential benefits of the biostasis compounds being tested?
The compounds are designed to improve preservation outcomes, thus enhancing the success rate of transplants and addressing organ scarcity issues.
Who can I contact for more information regarding VPS advancements?
Interested parties can contact Rafael Veraza, CEO of VPS, at 210-977-0191 for inquiries or additional information.
